Renaissance Technologies
EVLO

Renaissance Technologies’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Renaissance Technologies’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,434
Closed -$151K – 3815
2020
Q3 		$151K Sell
1,434
-365
-20% -$33.3K ﹤0.01% 3160
2020
Q2 		$176K Buy
1,799
+420
+30% +$36.8K ﹤0.01% 3189
2020
Q1 		$104K Sell
1,379
-81
-6% -$7.71K ﹤0.01% 3222
2019
Q4 		$119K Buy
1,460
+735
+101% +$82.2K ﹤0.01% 3291
2019
Q3 		$88K Buy
+725
New +$99.7K ﹤0.01% 3272

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies's EVLO Position: Q4 2020 in Review

Renaissance Technologies sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2020, closing a stake of 1,434 shares — an estimated $151K sold.

Renaissance Technologies first reported a position in EVLO in Q3 2019 and held it in 5 quarters. The position peaked at $176K in Q2 2020. 49 funds tracked by Wall St. Rank hold EVLO as of Q4 2020.

  • Renaissance Technologies reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Renaissance Technologies sold 1,434 Evelo Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $151K.
  • Renaissance Technologies first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Renaissance Technologies's Evelo Biosciences, Inc. Common Stock position peaked at $176K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2020.

Based on Renaissance Technologies's 13F filing for Q4 2020, filed 10 Feb 2021.